BioCentury
ARTICLE | Clinical News

LYS-GM101 regulatory update

January 20, 2017 10:41 PM UTC

Lysogene said FDA granted rare pediatric disease designation to LYS-GM101 to treat GM1 gangliosidosis. The company plans to begin a Phase I/II trial of LYS-GM101 in 1H18. The product is an adeno-assoc...

BCIQ Company Profiles

Lysogene S.A.